16 Congress Of
Total Page:16
File Type:pdf, Size:1020Kb
16 th Congress of making the difference in medication use 30 March – 1 April 2011, Vienna - Austria “Hospital pharmacists in a changing world – opportunities and challenges” The European Association of Hospital Pharmacists (EAHP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education The European Association of Hospital Pharmacists represents more than 21,000 hospital pharmacists in 31 European countries and is the only European federation of hospital pharmacists in Europe. EAHP warmly thanks the continued support of our Platinum Partner, Amgen and Gold Partners, Bayer HealthCare and Pfizer ABSTRACT BOOK Come and visit us Congress of EAHP, at standth No. 33 during the 16 30 March–1 April 2011, Vienna. Protect your investments Protecting what’s outside the vial is just as important as protecting what’s inside the vial. You can protect both with the only closed- system drug transfer device that has been clinically proven to prevent human uptake of hazardous drug and shown to help maintain the microbiological integrity of the drug vial.1 For more information on PhaSeal, visit us at stand No. 33. 1De Prijck, K, D’Haese E, Vandenbroucke J et al. Microbiological challenge of four protective devices for the reconstitution of cytotoxic agents. Soc. Appl. Microbiol. 2008; 47: 543-548. Carmel Pharma AB Aminogatan 30, SE-431 53 Mölndal, Sweden Tel: +46 31 703 04 00 Fax: +46 31 703 04 04 E-mail: [email protected] www.carmelpharma.com TABLE OF CONTENTS AND INFORMATION General information……………………………………………………………………………………………………………1 EAHP-EPSA award…………………………………………………………………………………………………………… 3 Poster award nominee oral presentations..............................................................................................................5 Call for abstracts – Milan 2012...............................................................................................................................12 Poster award nominee oral presentations............................................................................................................13 17th Congress of the EAHP – preliminary programme..........................................................................................14 Poster award nominee oral presentations............................................................................................................15 Abstracts: General and risk management, patient safety (including: medication errors, quality control)....................16 Technology (including: robots for production, incompatibilities, drug production and analytics, crs)..... 67 Drug supply / logistics (including: computer-aided drug dispatching and ward pharmacies)....................76 Drug information (i. anti-infectives, ii. cytostatics, iii. others)........................................................................ 83 Pharmacotherapy: pharmacokinetics and pharmacodynamics (including: ADE, TDM, DUE)................... 102 Other hospital pharmacy topics (including: medical devices)...................................................................... 114 Clinical pharmacy and clinical trials (including case series).........................................................................142 BEAM Summit 2010............................................................................................................................................183 Index of authors.................................................................................................................................................... 186 GENERAL INFORMATION - The poster judging will take place on Thursday, 31 March 2011. - Poster presenters must check in with the hostesses in the poster area (main entrance area of the congress centre) on Wednesday, 30th March, and they will assist participants with hanging their posters in the proper area. - The poster prize winners must be present at the closing ceremony on Friday, 1st April in order to win. DISCLAIMER EAHP makes no representations or warantees of any kind expressed or implied about the completeness, accuracy, reliability, suitability or availability with respect to the content of the abstracts and related graphics and tables. Any reliance you place on such information is therefore at your own risk. In no event will EAHP be reliable for any loss or dammage arrising from or in connection with the content of these abstracts. POSTER AWARD Encouragement prize for investigators The best abstracts/posters – with regards to aspects like originality, scientific quality and practical applicability – will be awarded with 3 prizes amounting EURO 750, EURO 500 and EURO 250. The winners will be announced at the closing ceremony of the congress. The winner must be present at the ceremony to receive his/her award. ©2010 Amgen Inc. All rights reserved. NP-AMG-602-2009 EAHP - EPSA award Recognising and honouring the best scientific research manuscript authored by an undergraduate student During its annual congress, EAHP will offer the Student Science Award to one or several European Pharmaceutical Student Association (EPSA) students, hence recognising and honouring the best scientific research manuscript authored by an undergraduate student. This award recognises a student's significant intellectual contribution which promotes the state of the art in hospital pharmacy and pharmaceutical research methods or theories. EPSA students and members are invited, through their organisation to submit manuscripts to an EAHP jury, who will select the best paper. The later will be presented during the congress and published in EJHP. Nature of the Award: First author of the winning article will receive free attendance to the 16th EAHP Congress in Vienna, €500 for travel and accommodation expenses, plus official recognition of the winner during the EAHP Congress closing ceremony. Any manuscript under the category of original research, case reports, scientific commentary and review articles, written by any undergraduate hospital pharmacy student(s) submitted for peer review by 15 January 2011 and approved for publication in the EJHP March 2011 issue in either the EJHP Practice or the EJHP Science journal, will be eligible for this competition. Submission Procedures: Any EPSA member may submit a manuscript following the EJHP Guidance for Authors. The manuscript shall be submitted to [email protected]. A complete copy of the manuscript must accompany the submission. A cover letter should be provided that states why the article represents an outstanding contribution to the field of hospital pharmacy and describes how it advances hospital pharmacy research, clinical, scientific, technical, economic and social aspects of pharmacy and therapeutics or affects health policy. Review and Selection: The EAHP- EPSA Student Science Award Jury serves as the review and selection committee for the Student Science Award. The jury will select the single best manuscript that shows significant insight into hospital pharmacy research from all those submitted based on its scientific quality and societal relevance. The committee has the discretion to not make the award in any given year. Award Presentation: The EAHP-EPSA Student Science Award will be presented during the award ceremony at the EAHP Annual Congress in Vienna, Austria on 1 April 2011. 3 ORAL, once-daily Xarelto®: Reshaping the future of clot prevention New Hip, High Level of Protection from VTE SUPERIOR EFFICACY in elective hip replacement surgery1 Total VTE risk reduction 70% in head to head comparison with enoxaparin1* REASSURING SAFETY Similar safety profi le compared with enoxaparin1,2 * RRR 70%; 95% CI, 49 to 82; (P<0.001) in modifi ed ITT population; total VTE: any DVT, non-fatal PE, and all-cause mortality. 1. Eriksson BI et al. N Engl J Med. 2008;358(26):2765–2775. 2. Kakkar AK et al. Lancet. 2008;372:31-39 Xarelto® 10 mg Filmtabletten Qualitative und quantitative Zusammensetzung: 10mg Rivaroxaban. Liste der sonstigen konzentration von Rivaroxaban führen und somit seine Wirksamkeit verringern und sind bei gleichzeitiger Einnahme Bestandteile: Mikrokristalline Cellulose, Croscarmellose-Natrium, Lactose-Monohydrat, Hypromellose, Natriumdo- mit Rivaroxaban mit Vorsicht anzuwenden. Besondere Vorsicht ist geboten bei der Anwendung von neuraxialer Anäs- decylsulfat, Magnesiumstearat, Macrogol (3350), Titanoxid (E171), Eisen(III)oxid (E172). Pharmakotherapeuti- thesie (Spinal/Epiduralanästhesie) oder Spinal/Epiduralpunktion. Xarelto enthält Lactose. Nebenwirkungen: Häu- sche Gruppe: Andere antithrombotische Mittel, ATC-Code: B01AX06 Anwendungsgebiete: Zur Prophylaxe fi g: Anstieg der GGT, Transaminasenanstieg (einschließlich erhöhte ALT und AST), Anämie (einschließlich entsprechen- venöser Thromboembolien (VTE) bei erwachsenen Patienten nach elektiven Hüft- oder Kniegelenks ersatzoperationen. der Laborparameter), Übelkeit, postoperative Blutungen (einschließlich postoperativer Anämie und Wundblutungen). Gegenanzeigen: Überempfi ndlichkeit gegen Rivaroxaban oder einen der sonstigen Bestandteile, klinisch relevan- Gelegentlich: Anstieg von Lipase, Amylase, Bilirubin im Blut, LDH und alkalischer Phosphatase, Tachykardie, Thrombo- te akute Blutungen, Lebererkrankungen, die mit einer Koagulopathie und einem klinisch relevanten Blutungsrisiko zytose (einschließlich erhöhter Thrombozytenzahl), Synkope (einschließlich Bewusstlosigkeit), Schwindel, Kopfschmer- verbunden sind, Schwangerschaft und Stillzeit. Vorsichtsmaßnahmen und Warnhinweise: Die Anwendung zen, Verstopfung,